Buy or sell guide
Should I Buy JNJ Stock Right Now?
A fast read on Wall Street conviction, live analyst commentary on X, and current valuation context for Johnson & Johnson.
Updated 2026-05-06
Wall Street currently rates JNJ buy with a 12-month price target of $249 (+10.5% upside). The sections below cover the bull case, key risks, and latest earnings context for JNJ.
Wall Street
Buy40 analystsConsensus target
$249 target (+10.5%)Current price $225.59Analyst sentiment
No recent analyst posts capturedWaiting for fresh postsEarnings context
EPS beat 0.7%Reported Tue Apr 14Wall Street verdict
Should I Buy JNJ Stock? Here's What Analysts Think
40 analysts currently cover JNJ. Below is their consensus rating, price target range, and implied upside.
According to 40 analysts, Johnson & Johnson (JNJ) is rated Buy with a consensus 12-month price target of $249 — representing 10% upside from today's price of $226. The bull case target is $283, the bear case is $208.
JNJBuy
From 40 analyst ratings- Current price
- $225.59
- Consensus Target
- $249 (+10.5% upside)
- Forward P/E
- 19.5x
- Coverage
- 40 analyst ratings
High target$283
Low target$208
At $225.59, the consensus setup implies +10.5% versus the 12-month target.
- 20 of 40 analysts lean Buy or Strong Buy, while 17 stay on Hold and 3 lean bearish.
- JNJ trades at roughly 19.5x forward earnings, so the bull case still depends on growth staying strong.
- Analysts span a wide range from $208 to $283, so conviction matters as much as the consensus target.
Below, compare that institutional answer with the live analyst commentary on X for JNJ right now.
4 of 4 analysts raised targetsBarclays $255Stifel $250Wells Fargo $263+1 more
May 2026Live commentary on X
What Analysts Are Saying About Johnson & Johnson Right Now
Real posts from high-reach stock analysts mentioning JNJ, shown exactly as written. Sorted by engagement — most discussed first.
No recent posts captured
No high-reach analysts have posted about JNJ in the last 7 days. Check back after the next earnings release or market-moving event.
Should you buy JNJ?
Is JNJ a Buy, Hold, or Sell Right Now?
A structured look at the bull case, the risks, and the most recent earnings execution for JNJ before you decide whether to buy, hold, or sell.
Current setup
JNJ beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.
Bull Case
What keeps the long thesis intact
- Strong Financial PerformanceJohnson & Johnson reported Q1 2026 sales growth of 9.9% to $24.1 billion and EPS of $2.14, raising 2026 guidance to $100.8 billion in sales and $11.55 adjusted EPS.
- Diversified PortfolioThe company's Innovative Medicine and MedTech divisions drive growth, with key drugs in oncology, immunology, and neuroscience, plus advancements in electrophysiology and cardiovascular products.
- Innovation and ApprovalsMultiple significant product approvals in Q1 2026, such as ICOTYDE and VARIPULSE Pro, highlight JNJ's focus on innovation.
- Analyst ConfidenceA majority of Wall Street analysts rate JNJ as 'Moderate Buy' or 'Buy,' with a consensus price target suggesting upside potential.
- Shareholder ReturnsJNJ has a history of increasing dividends, demonstrating commitment to shareholder value.
- Market StabilityWith a market cap exceeding $547 billion, JNJ is a stable leader in healthcare.
Wall Street rates JNJ buy, giving the bull case institutional backing from 40 analysts.
Watch Out For
What can break the setup quickly
- Valuation ConcernsJNJ's high P/E ratio suggests potential overvaluation relative to earnings.
- Insider SellingRecent insider selling by executives may indicate reduced confidence in future performance.
- Technical HeadwindsThe stock trades below its 50-day moving average, signaling a potential bearish trend.
- Profit-Taking VolatilityRecent profit-taking after strong earnings could lead to price volatility.
- Litigation RisksOngoing talc and opioid lawsuits pose financial and reputational risks.
- Stelara CliffLoss of exclusivity for Stelara and biosimilar competition present challenges.
Watch whether new negative commentary on JNJ points to these structural risks or is simply reacting to short-term price moves.
JNJ Earnings Reaction — What the Last Quarter Showed
Last Quarter
- EPS
- $2.70 vs $2.68 est.Beat 0.7%
- Revenue
- $24.1B vs $23.6B est.Beat 1.9%
Full JNJ Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy JNJ Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See JNJ's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs JNJ Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare with Peers
Compare business quality, growth, and profitability against top sector peers.
Start ComparisonJNJ — Frequently Asked Questions
Quick answers to the most common questions about buying JNJ stock.
Should I buy JNJ stock right now?
Verdict
JNJ has modest upside — analysts rate it "Buy" with a $249 target, implying +10.5% from today's $225.59. This is informational only — verify the data and consider your own risk tolerance before deciding.
Is now a good time to buy JNJ?
Timing
Timing depends on your horizon, but the data signals are: consensus rating "Buy" with +10.5% upside to the $249 target. In the past 30 days, 4 of 4 covering analysts raised their price targets — a bullish signal.
What is the price target for JNJ stock?
Price Target
JNJ's consensus 12-month price target is $249, set by 40 Wall Street analysts. The bull case high is $283 and the bear case low is $208. From the current price of $225.59, this implies +10.5% upside.
Is JNJ overvalued or undervalued?
Valuation
JNJ appears fairly valued — the $249 consensus target is roughly in line with today's $225.59 (+10.5%). It trades at a forward P/E of 19.5x. Targets range from $208 (bear) to $283 (bull), reflecting different assumptions about growth and margins.
Should I buy JNJ before earnings?
Earnings
JNJ reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $249 target. Consider position sizing rather than going all-in pre-print.
What are analysts saying about JNJ stock?
Coverage
Of 40 analysts covering Johnson & Johnson (JNJ): 0 Strong Buy, 20 Buy, 17 Hold, 3 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $249 (range $208–$283). Bullish analysts outnumber bearish by more than 2-to-1.
What are the risks of buying JNJ stock?
Risks
3 of the 40 analysts covering JNJ rate it Sell or Strong Sell. Common concerns include valuation stretch, slowing growth, and sector-specific headwinds — see the Bull vs. Risk cards above for the specific theses on Johnson & Johnson.
This page is for informational purposes only and does not constitute financial advice. Always conduct your own research before investing.